文献速递泌尿生殖介入PETMR

18F-氟代环丁氨酸PET/MRI用于高危前列腺癌患者术前淋巴结分期

18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
PubMed 文献 · Eur Radiol · 2018-01-02

28例高危前列腺癌患者术前接受同期18F-氟代环丁氨酸PET/MRI,并按预设八区模板切除淋巴结。患者层面MRI和PET的敏感度/特异度分别为40%/87.5%和40%/100%,区域层面分别为35%/95.7%和30%/100%。同期18F-氟代环丁氨酸PET/MRI特异度高但敏感度低,PET阳性提示转移负荷更高。

要点

  • 18F-氟代环丁氨酸PET/MRI对淋巴结转移特异度高(患者层面PET 100%、MRI 87.5%),但敏感度低(均40%)。
  • 真阳性区域淋巴结转移灶显著大于假阴性区域,转移灶大小是检出重要因素。
  • PET阳性N1患者转移负荷高于PET阴性N1患者。

核心结论

  • 同期18F-氟代环丁氨酸PET/MRI检测高危前列腺癌患者淋巴结转移特异度高但敏感度低;PET/MRI阳性提示转移负荷高于阴性。

研究设计与样本

  • 前瞻性研究,28例高危前列腺癌患者术前接受同期18F-氟代环丁氨酸PET/MRI,按预设八区模板切除淋巴结,以区域病理为参考标准。

诊断标准与关键数值

  • 患者层面检测盆腔淋巴结转移:MRI敏感度40%、特异度87.5%;PET敏感度40%、特异度100%。
  • 区域层面检测盆腔淋巴结转移:MRI敏感度35%、特异度95.7%;PET敏感度30%、特异度100%。

临床应用与阅片要点

  • 作者认为18F-氟代环丁氨酸PET/MRI敏感度不足以替代扩大盆腔淋巴结清扫(ePLND)。
  • 作者提出18F-氟代环丁氨酸PET/MRI可能用于辅助手术和选择辅助治疗。
  • PET阳性患者较PET阴性患者有更广泛的病变。
  • 转移淋巴结大小是检出重要因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the diagnostic potential of simultaneous 18F-fluciclovine PET/MRI for pelvic lymph node (LN) staging in patients with high-risk prostate cancer.

METHODS: High-risk prostate cancer patients (n=28) underwent simultaneous 18F-fluciclovine PET/MRI prior to surgery. LNs were removed according to a predefined template of eight regions. PET and MR images were evaluated for presence of LN metastases according to these regions. Sensitivity/specificity for detection of LN metastases were calculated on patient and region basis. Sizes of LN metastases in regions with positive and negative imaging findings were compared with linear mixed models. Clinical parameters of PET-positive and -negative stage N1 patients were compared with the Mann-Whitney U test.

RESULTS: Patient- and region-based sensitivity/specificity for detection of pelvic LN metastases was 40 %/87.5 % and 35 %/95.7 %, respectively, for MRI and 40 %/100 % and 30 %/100 %, respectively, for PET. LN metastases in true-positive regions were significantly larger than metastases in false-negative regions. PET-positive stage N1 patients had higher metastatic burden than PET-negative N1 patients.

CONCLUSION: Simultaneous 18F-fluciclovine PET/MRI provides high specificity but low sensitivity for detection of LN metastases in high-risk prostate cancer patients. 18F-Fluciclovine PET/MRI scan positive for LN metastases indicates higher metastatic burden than negative scan.

KEY POINTS: • 18F-Fluciclovine PET/MRI has high specificity for detection of lymph node metastasis. • 18F-Fluciclovine PET/MRI lacks sensitivity to replace ePLND. • 18F-Fluciclovine PET/MRI may be used to aid surgery and select adjuvant therapy. • 18F-Fluciclovine PET-positive patients have more extensive disease than PET-negative patients. • Size of metastatic lymph nodes is an important factor for detection.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Selnæs KM, Krüger-Stokke B, Elschot M, et al. 18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur Radiol. 2018. PMID: 29294158. doi:10.1007/s00330-017-5213-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。